Immune cell therapy shows promise for tough leukemia cases
NCT ID NCT04220684
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This early-stage trial tested the safety of using donor natural killer (NK) cells to treat acute myeloid leukemia (AML) that had returned or not responded to standard treatments. Nineteen patients received these immune cells to see if they could help fight the cancer without causing severe side effects. The main goals were to find the safest dose and track any negative reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 24344, United States
Conditions
Explore the condition pages connected to this study.